Plant Name: Cannabis sativa
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| CNR1; GPR55; CHRM2; FFAR1; FFAR4; CHRM1; CNR2; HTR2C; CHRM4; | |
| TSHR; | |
| GPR18; | |
| ACHE; | |
| FAAH; TDP1; RECQL; PKM; TERT; GLO1; HSD17B1; AKR1B1; HSD17B10; ALOX12; HPGD; ALOX15; NOX4; ALDH1A1; USP2; TNKS; PARP1; TNKS2; POLB; CD38; | |
| GLRA1; | |
| TRPV1; | |
| CFTR; | |
| GSK3B; SYK; FLT3; MAPK1; CDK6; CSNK2A1; | |
| CA2; CA12; CA7; CA4; | |
| PPARA; PPARD; PPARG; | |
| AR; | |
| ESR2; ESR1; | |
| NR1I2; | |
| KDM4E; | |
| MAOA; PTGS2; PTGS1; ALOX5; XDH; | |
| MMP9; MMP12; MMP2; | |
| TLR2; | |
| HIF1A; TP53; | |
| SLCO1B3; SLCO1B1; | |
| ABCG2; ABCC1; | |
| LMNA; NPC1; MAPT; FABP3; FABP5; FABP2; FABP4; THPO; APP; TTR; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
| Family A G protein-coupled receptor | GPR18 | N-arachidonyl glycine receptor | Q14330 | CHEMBL2384898 |
| Glycine receptor | GLRA1 | Glycine receptor subunit alpha-1 | P23415 | CHEMBL5845 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group I | NR1I2 | Pregnane X receptor | O75469 | CHEMBL3401 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | CNR1 | Cannabinoid CB1 receptor | P21554 | CHEMBL218 |
| Small molecule receptor (family A GPCR) | GPR55 | G-protein coupled receptor 55 | Q9Y2T6 | CHEMBL1075322 |
| Small molecule receptor (family A GPCR) | CHRM2 | Muscarinic acetylcholine receptor M2 | P08172 | CHEMBL211 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | CHRM1 | Muscarinic acetylcholine receptor M1 | P11229 | CHEMBL216 |
| Small molecule receptor (family A GPCR) | CNR2 | Cannabinoid CB2 receptor | P34972 | CHEMBL253 |
| Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
| Small molecule receptor (family A GPCR) | CHRM4 | Muscarinic acetylcholine receptor M4 | P08173 | CHEMBL1821 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transient receptor potential channel | TRPV1 | Vanilloid receptor | Q8NER1 | CHEMBL4794 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 2.768E-10 | 9.880E-08 | CA2, CA7, CD38, CDK6, CFTR, CNR1, HIF1A, HTR2C, MAPK1, NPC1, PARP1, PTGS2, SYK, TNKS, TNKS2, TRPV1 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.241E-09 | 6.026E-07 | AR, CA12, CA2, CA4, CA7, ESR1, ESR2, GLO1, GLRA1, MMP12, MMP2, MMP9, NR1I2, PARP1, PPARA, PPARD, PPARG, TNKS, TP53 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.364E-09 | 6.202E-07 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP3A4, XDH |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 4.394E-09 | 1.100E-06 | ABCC1, ALOX12, ALOX15, ALOX5, SYK, TLR2 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 4.996E-09 | 1.222E-06 | CA2, CA7, CFTR, CNR1, HIF1A, MAPK1, NPC1, PTGS2, SYK, TNKS, TNKS2 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 5.549E-09 | 1.313E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP3A4, NOX4, PTGS1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 6.536E-09 | 1.514E-06 | ALOX12, ALOX15, ALOX5, HPGD, PTGS2 |
| MF | Unclassified; | GO:0004872; receptor activity | 4.316E-08 | 8.032E-06 | AR, CHRM1, CHRM2, CHRM4, CNR1, CNR2, ESR1, ESR2, FFAR1, FFAR4, FLT3, GLRA1, GPR18, GPR55, HPGD, HTR2C, NPC1, NR1I2, PPARA, PPARD, PPARG, TLR2, TRPV1, TSHR |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.625E-08 | 8.353E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.913E-08 | 8.769E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0004949; cannabinoid receptor activity | 8.521E-08 | 1.461E-05 | CNR1, CNR2, GPR55 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 1.051E-07 | 1.774E-05 | ABCG2, ACHE, APP, CD38, CSNK2A1, ESR1, ESR2, FLT3, HPGD, MAPK1, MAPT, MMP9, PARP1, PKM, PPARG, PTGS2, SMN1, SMN2, TERT, TP53, TRPV1, TTR, USP2, XDH |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.764E-07 | 2.784E-05 | CYP1A2, CYP2A6, CYP3A4, NR1I2 |
| BP | GO:0009987; cellular process | GO:0038171; cannabinoid signaling pathway | 3.398E-07 | 4.835E-05 | CNR1, CNR2, GPR55 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.815E-07 | 6.636E-05 | CA12, CA2, CA4, CA7 |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 6.643E-07 | 8.875E-05 | ABCC1, APP, CFTR, CHRM1, CHRM2, CHRM4, CNR1, CNR2, FFAR1, FFAR4, FLT3, GLRA1, GPR18, GPR55, HTR2C, NPC1, SLCO1B1, SLCO1B3, TLR2, TRPV1, TSHR |
| BP | GO:0050896; response to stimulus | GO:0007197; adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway | 8.467E-07 | 1.085E-04 | CHRM1, CHRM2, CHRM4 |
| MF | GO:0060089; molecular transducer activity | GO:0016907; G-protein coupled acetylcholine receptor activity | 8.467E-07 | 1.085E-04 | CHRM1, CHRM2, CHRM4 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.473E-06 | 1.751E-04 | CA12, CA2, CA4, CA7, CFTR |
| BP | GO:0050896; response to stimulus | GO:0007207; phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway | 1.688E-06 | 1.924E-04 | CHRM1, CHRM2, CHRM4 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 1.837E-06 | 2.062E-04 | AR, ESR1, ESR2, NR1I2, PPARA, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 2.069E-06 | 2.275E-04 | CYP1A1, POLB, PPARG, TP53 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.069E-06 | 2.275E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2A6 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 2.308E-06 | 2.500E-04 | AR, CYP3A4, ESR1, ESR2, HSD17B1, NPC1 |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 2.520E-06 | 2.677E-04 | HPGD, MMP2, MMP9, TERT |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 3.013E-06 | 3.080E-04 | MAPT, NOX4, PTGS2, TP53, TRPV1, XDH |
| BP | GO:0050896; response to stimulus | GO:0014074; response to purine-containing compound | 3.981E-06 | 3.959E-04 | APP, CFTR, NOX4, PPARG, PTGS2, TP53, TRPV1 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 4.313E-06 | 4.156E-04 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 4.836E-06 | 4.598E-04 | AR, CFTR, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
| BP | GO:0050896; response to stimulus | GO:0048545; response to steroid hormone | 5.968E-06 | 5.483E-04 | AR, CA2, CD38, FLT3, NPC1, PARP1, PTGS2, TLR2 |
| BP | GO:0032501; multicellular organismal process | GO:0051241; negative regulation of multicellular organismal process | 6.310E-06 | 5.701E-04 | ALOX12, APP, CD38, CDK6, FFAR4, GLRA1, GPR18, GPR55, GSK3B, HIF1A, LMNA, PPARD, PPARG, PTGS2, TERT, TLR2, XDH |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 6.988E-06 | 6.185E-04 | HIF1A, LMNA, PPARD, PTGS2, TERT, TP53 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 7.282E-06 | 6.394E-04 | AR, ESR1, ESR2, NR1I2, PPARA, PPARD, PPARG |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 9.997E-06 | 8.277E-04 | CA2, CA7, CFTR |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 9.997E-06 | 8.277E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0051179; localization | GO:0042908; xenobiotic transport | 9.997E-06 | 8.277E-04 | ABCC1, ABCG2, NR1I2 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.246E-05 | 9.832E-04 | CNR2, CYP19A1, FFAR4, PPARA, PPARD, PPARG |
| BP | GO:0023052; signaling | GO:0032024; positive regulation of insulin secretion | 1.301E-05 | 1.022E-03 | CD38, CFTR, FFAR1, HIF1A, PPARD |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 1.307E-05 | 1.024E-03 | AR, ESR1, ESR2, NR1I2, PPARA, PPARD, PPARG |
| BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 1.370E-05 | 1.062E-03 | AR, CYP19A1, ESR1 |
| BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 1.549E-05 | 1.179E-03 | CNR1, CYP1B1, GSK3B, HPGD, MAPT, MMP9, NOX4, PPARG, PTGS2, TP53, TRPV1, XDH |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.935E-05 | 1.427E-03 | CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.959E-05 | 1.427E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 1.959E-05 | 1.427E-03 | PTGS1, PTGS2 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 1.959E-05 | 1.427E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.959E-05 | 1.427E-03 | ALOX12, ALOX15 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.940E-05 | 1.427E-03 | ABCC1, CA2, CA4, HPGD, SLCO1B1, SLCO1B3, TSHR |
| BP | GO:0051179; localization | GO:0015850; organic hydroxy compound transport | 2.397E-05 | 1.686E-03 | ABCG2, CFTR, NPC1, SLCO1B1, SLCO1B3, SYK |
| BP | GO:0022414; reproductive process | GO:0007566; embryo implantation | 2.408E-05 | 1.686E-03 | MMP2, MMP9, PPARD, PTGS2 |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 2.807E-05 | 1.910E-03 | ALOX15, APP, FFAR4, GPR55, HTR2C, NOX4, THPO |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 2.876E-05 | 1.939E-03 | FABP3, FFAR1, PPARG, PTGS2, TLR2 |
| BP | GO:0009987; cellular process | GO:0080135; regulation of cellular response to stress | 2.990E-05 | 2.009E-03 | APP, CDK6, GSK3B, HIF1A, MAPK1, MAPT, PARP1, PTGS2, SYK, TERT, TP53, XDH |
| BP | GO:0050896; response to stimulus | GO:0032868; response to insulin | 3.653E-05 | 2.353E-03 | FABP3, PARP1, PKM, PPARA, PPARG, TLR2 |
| BP | GO:0051179; localization | GO:0070198; protein localization to chromosome, telomeric region | 3.730E-05 | 2.389E-03 | TERT, TNKS, TNKS2 |
| BP | Unclassified; | GO:0032845; negative regulation of homeostatic process | 4.453E-05 | 2.803E-03 | CD38, HTR2C, PARP1, TNKS, TNKS2, TRPV1 |
| MF | GO:0005215; transporter activity | GO:0005319; lipid transporter activity | 4.453E-05 | 2.803E-03 | ABCC1, ABCG2, FABP3, NPC1, SLCO1B1, SLCO1B3 |
| BP | GO:0009987; cellular process | GO:0034605; cellular response to heat | 4.747E-05 | 2.954E-03 | MAPT, PTGS2, TP53, TRPV1 |
| BP | GO:0065007; biological regulation | GO:0008217; regulation of blood pressure | 5.389E-05 | 3.278E-03 | AR, CNR1, PPARA, PPARG, PTGS1, PTGS2 |
| BP | GO:0002376; immune system process | GO:0001774; microglial cell activation | 5.539E-05 | 3.332E-03 | MAPT, TLR2, TRPV1 |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 5.539E-05 | 3.332E-03 | MAPK1, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 5.539E-05 | 3.332E-03 | CYP1A1, PPARD, PPARG |
| BP | GO:0032501; multicellular organismal process | GO:0014005; microglia development | 5.861E-05 | 3.449E-03 | APP, TLR2 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 5.861E-05 | 3.449E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 5.861E-05 | 3.449E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 5.861E-05 | 3.449E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 5.861E-05 | 3.449E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 5.861E-05 | 3.449E-03 | ALOX12, ALOX15 |
| BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 7.632E-05 | 4.408E-03 | APP, MAPK1, PARP1, PTGS2, TLR2 |
| BP | GO:0032502; developmental process | GO:0007568; aging | 7.698E-05 | 4.435E-03 | CNR1, CYP1A1, NOX4, POLB, PTGS2, TERT, TP53 |
| BP | GO:0002376; immune system process | GO:0002683; negative regulation of immune system process | 8.078E-05 | 4.616E-03 | ALOX15, CDK6, CNR1, CNR2, CYP19A1, GPR18, GPR55, MMP12, PPARG |
| BP | GO:0007610; behavior | GO:0007611; learning or memory | 8.572E-05 | 4.848E-03 | APP, CNR1, HIF1A, MAPK1, MAPT, PTGS2, TLR2 |
| BP | GO:0032501; multicellular organismal process | GO:0019233; sensory perception of pain | 9.081E-05 | 5.109E-03 | CNR1, CNR2, MAPK1, PTGS2 |
| MF | GO:0005488; binding | GO:0019902; phosphatase binding | 9.172E-05 | 5.136E-03 | MAPK1, MAPT, PPARA, PPARG, SYK, TP53 |
| MF | GO:0005488; binding | GO:0001223; transcription coactivator binding | 9.196E-05 | 5.136E-03 | ESR1, PPARA, TERT |
| BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 9.774E-05 | 5.415E-03 | NOX4, PARP1, POLB, TP53 |
| MF | GO:0005488; binding | GO:0043621; protein self-association | 9.774E-05 | 5.415E-03 | ACHE, FLT3, PPARG, TP53 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 1.108E-04 | 6.075E-03 | HIF1A, MMP12, MMP2, MMP9, TRPV1 |
| CC | GO:0044464; cell part | GO:0042995; cell projection | 1.135E-04 | 6.208E-03 | AKR1B1, APP, CA2, CDK6, CHRM1, CHRM2, CNR1, CNR2, GLRA1, HIF1A, MAPK1, MAPT, PKM, PTGS2, SMN1, SMN2, TLR2 |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 1.169E-04 | 6.250E-03 | TNKS, TNKS2 |
| BP | GO:0032501; multicellular organismal process | GO:0032640; tumor necrosis factor production | 1.169E-04 | 6.250E-03 | APP, TLR2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.169E-04 | 6.250E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.169E-04 | 6.250E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.169E-04 | 6.250E-03 | CYP1A2, CYP3A4 |
| MF | GO:0005488; binding | GO:0005497; androgen binding | 1.169E-04 | 6.250E-03 | ALDH1A1, AR |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 1.174E-04 | 6.250E-03 | CHRM1, CHRM2, CHRM4, CNR1, CNR2, FFAR1, FFAR4, FLT3, GPR18, GPR55, HPGD, HTR2C, NPC1, PPARG, TRPV1, TSHR |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 1.210E-04 | 6.363E-03 | AKR1B1, CYP1B1, MAPK1, MMP9, TP53 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 1.210E-04 | 6.363E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, XDH |
| BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 1.234E-04 | 6.461E-03 | HIF1A, TERT, TP53 |
| BP | GO:0009987; cellular process | GO:0045600; positive regulation of fat cell differentiation | 1.383E-04 | 7.069E-03 | HTR2C, PPARD, PPARG, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.415E-04 | 7.182E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 1.535E-04 | 7.650E-03 | ALOX12, APP, HIF1A, MAPK1, MMP9, NOX4, PTGS2, TERT, TP53 |
| BP | GO:0050896; response to stimulus | GO:0035902; response to immobilization stress | 1.612E-04 | 7.941E-03 | CYP1A1, CYP1A2, PPARG |
| CC | GO:0044464; cell part | GO:0043204; perikaryon | 1.626E-04 | 7.965E-03 | CNR2, GLRA1, MAPK1, SMN1, SMN2 |
| BP | GO:0050896; response to stimulus | GO:0045471; response to ethanol | 1.693E-04 | 8.210E-03 | CNR1, GLRA1, HPGD, POLB, TP53 |
| MF | GO:0005488; binding | GO:0001085; RNA polymerase II transcription factor binding | 1.693E-04 | 8.210E-03 | AR, ESR1, GSK3B, PPARA, TP53 |
| BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 1.826E-04 | 8.776E-03 | HIF1A, PPARD, TP53 |
| BP | GO:0065007; biological regulation | GO:0044092; negative regulation of molecular function | 1.860E-04 | 8.901E-03 | APP, CNR1, CNR2, CSNK2A1, CYP1B1, ESR1, FABP4, GSK3B, MAPT, MMP9, PPARA, PPARG, PTGS2, TNKS, TP53 |
| BP | GO:0009987; cellular process | GO:0071396; cellular response to lipid | 1.870E-04 | 8.929E-03 | AR, CDK6, CFTR, ESR1, FLT3, NPC1, PPARD, PPARG |
| BP | GO:0023052; signaling | GO:0050805; negative regulation of synaptic transmission | 1.898E-04 | 9.025E-03 | ACHE, CD38, CNR2, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 1.942E-04 | 9.096E-03 | ALOX12, ALOX15 |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 1.942E-04 | 9.096E-03 | PPARA, PPARG |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.942E-04 | 9.096E-03 | CYP1A1, CYP3A4 |
| CC | GO:0044464; cell part | GO:0043005; neuron projection | 2.025E-04 | 9.363E-03 | APP, CA2, CHRM1, CHRM2, CNR1, CNR2, GLRA1, MAPK1, MAPT, PTGS2, SMN1, SMN2 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 2.057E-04 | 9.411E-03 | CYP19A1, CYP1A2, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0003950; NAD+ ADP-ribosyltransferase activity | 2.057E-04 | 9.411E-03 | PARP1, TNKS, TNKS2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.254E-09 | 2.233E-07 | APP; MAOA; ALOX5; ALOX15; HTR2C; MAPK1; ALOX12; PTGS2; PTGS1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.291E-07 | 5.745E-06 | AR; GSK3B; CDK6; FLT3; MMP2; MAPK1; PPARG; PTGS2; HIF1A; TP53; MMP9; PPARD |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 7.232E-08 | 4.291E-06 | HSD17B1; ALOX5; CYP1A1; CYP1B1; PTGS2; CYP19A1 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.844E-08 | 1.641E-06 | FABP2; FABP3; FABP4; FABP5; PPARG; PPARA; PPARD |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.792E-07 | 6.380E-06 | HSD17B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 6.065E-07 | 1.697E-05 | SLCO1B1; CA2; SLCO1B3; CYP3A4; CFTR; ABCG2 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 4.341E-06 | 7.025E-05 | MAOA; ALOX15; AKR1B1; ALOX12; PTGS2; CYP3A4; CYP19A1; HSD17B10; PTGS1; CYP2A6; PKM; HSD17B1; ALOX5; CYP1A2; ALDH1A1; CYP1A1; CD38; XDH |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 2.984E-06 | 5.312E-05 | CHRM2; GLRA1; CHRM1; CNR2; CNR1; CHRM4; HTR2C; TRPV1; TSHR |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.428E-06 | 2.824E-05 | CYP2A6; CYP1A2; CYP1A1; CYP1B1; CYP3A4; PTGS2 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 6.975E-06 | 1.035E-04 | ALOX5; ALOX15; ALOX12; PTGS2; PTGS1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 2.730E-05 | 2.826E-04 | MMP2; MAPK1; TP53; HIF1A; ESR1; MMP9; TLR2 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.024E-05 | 1.301E-04 | PKM; FLT3; MAPK1; TP53; HIF1A |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 8.814E-06 | 1.207E-04 | CYP2A6; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.560E-05 | 1.851E-04 | CYP2A6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.099E-04 | 9.316E-04 | CHRM2; GSK3B; CHRM1; CDK6; SYK; MAPK1; TP53; TLR2 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 6.806E-05 | 6.377E-04 | MMP2; MAPK1; ESR1; MMP9; ESR2 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.171E-04 | 9.478E-04 | CHRM2; ACHE; CHRM1; CHRM4; MAPK1 |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 7.266E-07 | 1.697E-05 | CA12; CA2; CA4; CA7 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 2.588E-05 | 2.826E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 2.185E-04 | 1.585E-03 | CHRM2; CHRM1; MAPK1; PPARA; CFTR; TSHR |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.562E-04 | 1.209E-03 | GSK3B; MAPK1; TP53; ESR1; HIF1A |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 2.564E-04 | 1.610E-03 | POLB; CDK6; PKM; SYK; MAPK1; TP53 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 9.869E-05 | 8.783E-04 | FABP4; PTGS2; TSHR; PTGS1 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 2.858E-05 | 2.826E-04 | MMP2; MAPK1; MMP9; TP53 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 2.928E-04 | 1.737E-03 | ABCC1; CDK6; CYP1B1; MAPK1; PTGS2; TP53; MMP9 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 3.025E-04 | 1.737E-03 | GSK3B; CDK6; CSNK2A1; TP53; TLR2 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 4.192E-04 | 2.332E-03 | CDK6; MAPK1; TP53; MMP9; TLR2 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.226E-04 | 1.585E-03 | CYP2A6; MAOA; CYP1A2; CYP3A4 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 2.624E-04 | 1.610E-03 | GSK3B; MAPK1; ESR1; ESR2 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 5.891E-04 | 3.177E-03 | GSK3B; AR; MAPK1; TP53 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 7.929E-04 | 4.032E-03 | APP; GSK3B; MAPK1; MAPT; HSD17B10 |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 9.473E-04 | 4.557E-03 | FAAH; CNR1; MAPK1; PTGS2 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.797E-03 | 7.651E-03 | GSK3B; SYK; CSNK2A1; CD38; TP53 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 6.953E-04 | 3.640E-03 | SYK; CSNK2A1; PARP1; PTGS2 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.080E-03 | 4.928E-03 | HPGD; FLT3; PPARG; TP53; MMP9 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 3.134E-03 | 1.162E-02 | PARP1; LMNA; MAPK1; TP53 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 2.605E-03 | 1.030E-02 | GSK3B; MAPK1; PPARA; TP53 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 3.297E-03 | 1.198E-02 | GSK3B; CSNK2A1; TP53; PPARD |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 7.598E-03 | 2.373E-02 | CHRM2; CHRM1; HTR2C; CD38 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 2.767E-03 | 1.071E-02 | CDK6; MAPK1; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.805E-03 | 7.651E-03 | CDK6; MAPK1; TP53 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.457E-03 | 6.484E-03 | GSK3B; MAPK1; TP53 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 2.587E-04 | 1.610E-03 | MAPK1; PPARG; TP53 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.900E-03 | 7.863E-03 | FLT3; MAPK1; PPARD |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 2.418E-03 | 9.781E-03 | GSK3B; MAPK1; TP53 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 2.889E-03 | 1.094E-02 | CDK6; MAPK1; TP53 |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 1.368E-02 | 3.865E-02 | CHRM2; CHRM1; CHRM4; MAPK1 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 3.554E-03 | 1.265E-02 | CDK6; MAPK1; TP53 |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 8.704E-03 | 2.625E-02 | HTR2C; ALOX12; TRPV1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 3.843E-03 | 1.291E-02 | CDK6; MAPK1; TP53 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 3.843E-03 | 1.291E-02 | GSK3B; SYK; MAPK1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.190E-02 | 3.474E-02 | MAPK1; PTGS2; MMP9 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 3.843E-03 | 1.291E-02 | MAPK1; PTGS2; TLR2 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 6.076E-03 | 1.966E-02 | CDK6; PTGS2; TP53 |
| hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 6.475E-03 | 2.058E-02 | THPO; FLT3; CD38 |
| hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 8.227E-03 | 2.525E-02 | CA2; CD38; CFTR |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.437E-02 | 3.996E-02 | ALOX5; MAPK1; TLR2 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 1.570E-02 | 4.171E-02 | SYK; MAPK1; PTGS1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.503E-02 | 4.052E-02 | GSK3B; MAPK1; TP53 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.503E-02 | 4.052E-02 | ABCC1; MAPK1; TP53 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.932E-02 | 4.914E-02 | SYK; MAPK1; PPARG |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.639E-02 | 4.290E-02 | GSK3B; CDK6; TP53 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.020E-03 | 4.776E-03 | CYP2A6; CYP3A4; XDH |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 8.951E-04 | 4.426E-03 | ABCC1; CFTR; ABCG2 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.587E-04 | 1.610E-03 | CYP1A2; ALOX15; CYP3A4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 7.629E-07 | 1.697E-05 | CYP2A6; CYP1A2; XDH |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 1.814E-02 | 4.679E-02 | PKM; MAPK1 |
| hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 1.282E-02 | 3.681E-02 | PKM; GLO1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 8.850E-03 | 2.625E-02 | POLB; PARP1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 4.360E-03 | 1.437E-02 | CA2; CA4 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Immune disorder | D80-D89 | CNR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | CNR1; FFAR1; PPARD; PTGS2; PPARG; PPARG |
| K00-K95: Diseases of the digestive system | Stomach ulcer | K25-K27 | CHRM1 |
| NA: NA | Suprapubic pain | NA | CHRM4 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; ESR1; TLR2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | TRPV1; CNR2; ALOX5 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT; CD38 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | CNR1; HTR2C; CHRM1; CHRM1; CHRM1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | CHRM4; CHRM4 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; SYK; TP53; MAPK1; FLT3; MMP9; TLR2; MMP2; PKM; CHRM4 |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | SYK; SYK; MMP12; TRPV1; PTGS2; CHRM2; ALOX5; ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; PTGS2; ABCC1; ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | CNR1; HTR2C; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR2C; MAOA |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| NA: NA | Moderate and severe psychomotor agitation | NA | CHRM4 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | CHRM1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; MMP12; CHRM1; ALOX5; CHRM4 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | TRPV1; CHRM4 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | CHRM1; TRPV1; TRPV1; CHRM4 |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; CHRM2 |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; PTGS2; PTGS2 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | SYK; AKR1B1; PTGS2; PTGS2; PTGS2; PTGS2; CNR2; ALOX5 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | CNR1; MMP2; TERT; PARP1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; ESR1; CNR2 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; ESR1; ESR1; TERT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; TERT |
| NA: NA | Peptic ulcer disease | NA | CHRM4 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; TLR2; MMP2; TERT; PTGS2 |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | CHRM4 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; MAOA; CHRM1; CHRM1; CHRM2; CHRM4 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | CHRM1; CHRM2; CHRM4; CHRM4; CHRM4 |
| C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR2C |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pathological pain | R52, G89 | TRPV1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | CHRM1; CHRM1; CHRM4; CHRM4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| NA: NA | Schizoaffective disorders | NA | CHRM1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | CNR1; HTR2C |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| NA: NA | Menopausal disorder | NA | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | CNR1; CHRM4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; CHRM1; MAPT |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1; MMP2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; ALOX5 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Organophosphate poisoning | T60.0 | CHRM4 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Urinary retention | R33 | CHRM4 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| H00-H59: Diseases of the eye and adnexa | Produce mydriasis and cycloplegia for diagnostic purposes | H57.04 | CHRM4 |
| NA: NA | Primary insomnia | NA | HTR2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; ESR1; TLR2; TERT |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | CNR1; PPARD; MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Central and peripheral nervous diseases | G96.9 | CHRM4 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | CNR1; PARP1 |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | TRPV1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3; TERT |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | CNR1; PTGS1; MAOA; CHRM1; TRPV1; PTGS2; PTGS2; CNR2 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HTR2C; APP; ESR1; CHRM1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nocturia | R35 | CHRM4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | CNR1; PPARG |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | CNR1 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | TRPV1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH; CHRM2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chemotherapy-induced nausea | R11 | CNR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1; AKR1B1; TRPV1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | CNR1; CNR1; CNR1; CNR1; CNR1; CNR1; HTR2C; HTR2C; PPARD; PPARD; PPARG |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; ALOX5 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | SYK; PTGS1; MMP12; FAAH; PTGS2; CNR2; ALOX5 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP; ACHE |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | CHRM1; TRPV1; CHRM2 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; MMP9 |
| NA: NA | Urgency | NA | CHRM4 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Stabilize muscle contractions | M00-M99 | CHRM2 |
| NA: NA | Dyslipidemia | NA | PPARD |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1; ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2C; MAOA; CHRM4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | CNR1; CNR1; CNR1; GSK3B; HTR2C; FFAR1; AKR1B1; PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Mydriasis diagnosis | H57.0 | CHRM4 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Acute or chronic pain | R52, G89 | TRPV1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Visceral spasms | R25.2 | CHRM1 |
| NA: NA | Uveitis | NA | CHRM4 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| NA: NA | Addiction | NA | CHRM2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| NA: NA | Abdominal stomach pain | NA | CHRM1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; AKR1B1; CHRM1; CHRM4 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PARP1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | CHRM2; CHRM4 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CNR1; AR; PTGS1; HTR2C; ACHE; ESR1; TRPV1; TRPV1; FAAH; PTGS2; PTGS2; PTGS2; PTGS2; PKM; CNR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | CNR1 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ESR1 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Acquired nystagmus | H55 | CHRM4 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; PTGS1; ESR1; MMP2 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C |
| K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | TRPV1 |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | SYK; ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GSK3B; APP; ACHE; ACHE; ACHE; MAOA; CHRM1; PTGS2; MAPT; CHRM2; PPARG; PPARG; CHRM4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| NA: NA | Excessive sweating | NA | CHRM1 |
| NA: NA | Extrapyramidal disorders secondary to neuroleptic drug therapy | NA | CHRM1 |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2; TERT; PARP1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; PTGS2; ABCC1; ABCC1; PPARG |
| NA: NA | Geographic retinal atrophy | NA | APP |
| NA: NA | GIST | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioma | C71 | APP |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | HTR2C; MAOA |
| NA: NA | Esophagus sensitivity | NA | TRPV1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| NA: NA | Male hypogonadism | NA | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR2C; HTR2C; MAOA; MAOA; FAAH |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CNR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HTR2C; ACHE; CYP3A4; MAOA; FAAH |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anorexia | F50.0-F50.1 | CNR1 |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PTGS2; PPARG |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | CHRM4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | CNR1; AR |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1; TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | CHRM1; FAAH |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
| NA: NA | Dystonia | NA | CHRM1 |
| NA: NA | Dysuria | NA | CHRM4 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; ESR1; PTGS2; PTGS2; PTGS2; PTGS2 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| NA: NA | Vomiting | NA | CHRM4 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | CHRM4; CHRM4 |
| NA: NA | Gastritis | NA | CHRM4 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; TP53; CD38 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; GSK3B; HIF1A; SYK; TP53; MAPK1; APP; FLT3; FLT3; MMP9; ACHE; ESR1; ESR1; TLR2; MMP2; PARP1; PTGS2; CSNK2A1; CD38 |
| J00-J99: Diseases of the respiratory system | Bronchodilator | J45 | CHRM4 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1; TP53; FLT3; MMP9 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | CHRM4 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| NA: NA | Functional bowel syndrome | NA | CHRM1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; CHRM4 |
| G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD; ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PTGS2; CNR2; PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | NR1I2; MMP12; PPARD; ALOX5 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Postherpetic neuralgia | B02.2, G44.847, G53.0 | CNR1; TRPV1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | SYK; ALOX5 |